loracarbef
Trade name: lorabid
Approved
Dec 31, 1991
Loracarbef (KT3777) is carbacephem antibiotic structurally identical to cefaclor, except that the sulfur atom of position 1 of the cephem nucleus has been replaced by carbon. It showed good affinity for penicillin-binding proteins. At low concentrations (< 2 mg/L) in vitro, it inhibits Streptococcus pneumoniae, S. pyogenes, beta-haemolytic streptococci groups B, C and G. Proteus mirabilis and Moraxella catarrhalis, including beta-lactamase-producing strains. At therapeutic plasma concentrations it is also active in vitro against most strains of Staphylococcus aureus, S. saprophyticus, Escherichia coli and beta-lactamase-positive and -negative strains of Haemophilus influenzae. Loracarbef has been indicated in the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms. — NCATS
Clinical trial activity
0 trials · 0 clinical orgs · 2 marketing orgs
Timeline
1990s
- Dec 28, 1991
Eli Lilly — First NDA Organization
- Dec 28, 1991
Eli Lilly — NDA Organization
- Dec 31, 1991
Earliest FDA Approval
- Dec 31, 1991
King Pharmaceuticals — NDA Secondary Org
Indications
Approved for
Mechanism of action
- Bacterial penicillin-binding proteinINHIBITOR
Bacterial penicillin-binding protein inhibitor
- D-alanyl-D-alanine carboxypeptidase DacB (dacB) ↗
- Peptidoglycan D,D-transpeptidase FtsI (ftsI) ↗
- Penicillin-binding protein 1A (mrcA) ↗
- Penicillin-binding protein 1B (mrcB) ↗
- D-alanyl-D-alanine carboxypeptidase DacA (dacA) ↗
- Peptidoglycan D,D-transpeptidase MrdA (mrdA) ↗
- D-alanyl-D-alanine carboxypeptidase DacC (dacC) ↗
Approval history
- approvedDec 31, 1991
Chemistry & pharmacology
SMILES
N[C@@H](C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(Cl)CC[C@H]12)c1ccccc1- Mol. weight
- 349.77 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Discontinued
Oral
Yes
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1013 ↗
- WikipediaLoracarbef ↗
- NCATSW72I5ZT78Z ↗
- ChEMBLCHEMBL1200610 ↗
Also known as
- 1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((aminophenylacetyl)amino)-3-chloro-8-oxo-, (6r-(6alpha,7beta(r*)))-
- anhydrous loracarbef
- anhydrous loracarbef
- carbac
- kt 3777
- kt-3777
- lilly brand of loracarbef
- lilly brand of loracarbef monohydrate
- lorabid
- lorabid
- lorabid
- lorabid
- lorabid
- loracarbef
- loracarbef
- loracarbef
- loracarbef
- loracarbef
- loracarbef
- loracarbef
- loracarbef
- loracarbef
- loracarbef
- loracarbef, anhydrous
- loracarbef, anhydrous
- loracarbef hydrate
- loracarbef hydrate
- loracarbef hydrate
- loracarbef monohydrate
- loracarbefum
- loracarbefum
- lorafem
- lorax
- loribid
- ly163892
- ly 163892
- ly-163892
- ly-163892
- ly-163892
- monarch brand of loracarbef monohydrate
- syntex brand of loracarbef monohydrate
- zambon brand of loracarbef monohydrate
Organizations
Marketing (2)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Eli Lilly | For profit | NDA | Dec 28, 1991 |
| King Pharmaceuticals | For profit | NDA2 | Dec 31, 1991 |